05.12.2016 21:19:00
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Shareholders of Agios Pharmaceuticals, Inc. - AGIO
NEW YORK, Dec. 5, 2016 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Agios and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
[Click here to join a class action]
At the 2016 American Society of Hematology meeting (December 3-6, 2016), Agios presented new data for its AG-348 and AG-519 molecules, in development for treatment of pyruvate kinase deficiency. The Company stated that a case of Grade 2 thrombocytopenia (a reduction of platelets in blood cells) was reported in a patient receiving AG-519, and that an ongoing severe adverse event of drug-related cholestatic hepatitis was observed in a bioavailability and food effect study after a dose of 300 mg.
On this news, Agios stock fell as much $9.03, or 15.85%, to $47.94 on December 5, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-shareholders-of-agios-pharmaceuticals-inc--agio-300373022.html
SOURCE Pomerantz LLP
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Agios Pharmaceuticals Incmehr Nachrichten
31.07.24 |
Ausblick: Agios Pharmaceuticals vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |